Agnieszka Grochowalska, MD
Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1144496209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 514 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,701 and has fallen 86.7% since, to $359 in 2025.
Across 514 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$692
- Sanofi-aventis U.S. LLC$628
- Boehringer Ingelheim$557
- Amgen$520
- AstraZeneca$425
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,724100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 219 | $1,557 |
| Lilly USA, LLC | 40 | $692 |
| Sanofi-aventis U.S. LLC | 32 | $628 |
| Boehringer Ingelheim | 21 | $557 |
| Amgen | 20 | $520 |
| AstraZeneca(2 entities) | 18 | $425 |
| AbbVie | 27 | $424 |
| Abbott | 11 | $315 |
| Dexcom, Inc. | 11 | $267 |
| Amneal Pharmaceuticals LLC | 12 | $265 |
| IBSA Pharma Inc. | 12 | $258 |
| Insulet Corporation | 13 | $241 |
| Corcept Therapeutics | 8 | $196 |
| Medtronic(2 entities) | 9 | $192 |
| Johnson & Johnson | 12 | $188 |
| Radius Health, Inc. | 7 | $155 |
| Amarin Pharma, Inc. | 8 | $147 |
| Merck | 8 | $118 |
| Lifescan, Inc. | 5 | $107 |
| Ascendis Pharma Endocrinology Inc | 1 | $94 |
| Mannkind Corporation | 4 | $80 |
| Shire North American Group Inc | 2 | $37 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $36 |
| BD | 2 | $34 |
| Cequr Corporation | 1 | $33 |
| Bayer | 1 | $30 |
| Pfizer | 2 | $25 |
| Senseonics, Incorporated | 1 | $24 |
| Valeritas, Inc. | 1 | $23 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$250
- FARXIGA$125
- EVENITY$125
- DEXCOM G6 TRANSMITTER$122
- FREESTYLE LIBRE 3$108
- RYBELSUS$101
How this compares
$7,735 in reported general payments places this provider in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $214,068 |
| JardianceEmpagliflozin | 97 | $103,632 |
| TrulicityDulaglutide | 41 | $82,505 |
| TymlosAbaloparatide | 15 | $60,753 |
| MounjaroTirzepatide | 27 | $59,778 |
| JanuviaSitagliptin Phosphate | 54 | $52,760 |
| FarxigaDapagliflozin Propanediol | 22 | $35,959 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $27,848 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $26,239 |
| SynthroidLevothyroxine Sodium | 197 | $21,059 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $16,764 |
| Humalog Kwikpen U-100Insulin Lispro | 54 | $12,343 |
| TirosintLevothyroxine Sodium | 39 | $10,312 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $8,776 |
| Novolog FlexpenInsulin Aspart | 33 | $7,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,557 | $214,068101 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $692 | $142,28368 claims |
| Boehringer IngelheimJardiance | $557 | $103,63297 claims |
| Radius Health, Inc.Tymlos | $155 | $60,75315 claims |
| MerckJanuvia | $118 | $52,76054 claims |
| AstraZenecaFarxiga | $425 | $35,95922 claims |
| AbbVieSynthroid | $424 | $21,059197 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $265 | $12,922564 claims |
| IBSA Pharma Inc.Tirosint | $258 | $10,31239 claims |
| PfizerLevoxyl | $25 | $1,16425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Trumbull
- Glenn RichTrumbull$210K
- Judith CastilloTrumbull$37K
- Jonathan FillmoreTrumbull$12K
- Joseph RosaTrumbull$8K
- Erika StrohmayerTrumbull$4K
- Linda WernerTrumbull$3K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.